A Phase 3 interventional study of V503 and Placebo in Warts, Genital and Neoplasms, Anal, sponsored by Merck Sharp & Dohme LLC. Completed at 22 sites in Japan. Open to male participants aged 16 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata — 2 open to participants now, 4 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Condylomata Acuminata.
Among the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, this one is the 7th largest by enrollment, is one of 2 that started in 2020, is one of 9 in phase 3, and was the 6th registered.
116 studies on the registry are indexed under Condylomata Acuminata; 11 are open to participants now.
Browse Condylomata Acuminata studies →2 of the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata are open now, in 3 countries. Recruiting first, the newest first:
Shanghai Bovax Biotechnology Co., Ltd. · Sites in China
Ages 9–45 · Women only · Healthy volunteers
National Institute of Hygiene and Epidemiology, Vietnam · Sites in Australia, Vietnam
Ages 18–26 · Women only · Healthy volunteers
By country, each count listing its studies:
Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →
Of the 6 Condylomata Acuminata studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 16 Years to 26 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2020.
This study's enrollment of 1,059 is above the median of 158 across 95 interventional studies indexed under Condylomata Acuminata.
Median enrollment 1,206 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
19 studies in Condylomata Acuminata by Merck & Co., Inc: none open now, 2 under way, 1 of them phase 3. Of 16 finished, 12 (75%) have results posted.
Among the 19 studies in Condylomata Acuminata by Merck & Co., Inc, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 14 in phase 3, and was the 18th registered.
Merck & Co., Inc’s Condylomata Acuminata studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 19 in Condylomata Acuminata:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate the efficacy of V503 in preventing human papillomavirus (HPV)-related anogenital persistent infection, and to evaluate the safety/tolerability of V503, in Japanese males who are 16 to 26 years of age. It is hypothesized that administration of a 3-dose regimen of V503 reduces the combined incidence of HPV 6/11/16/18-related anogenital persistent infection, as well as the combined incidence of HPV 31/33/45/52/58-related anogenital persistent infection, compared with placebo.
The study includes a Base Study to assess efficacy and safety of V503, and an Extension Study. Participants who received placebo in the Base Study will be eligible to receive V503 vaccine on Day 1, Month 2, and Month 6 of the Extension Study. Participants who received less than 3 doses of V503 in the Base Study will be offered the opportunity to complete the 3-dose regimen in the Extension Study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the base study, participants receive an intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.
Biological: V503
In the base study, participants receive an IM injection of placebo at Day 1, Month 2, and Month 6.
Other: Placebo
Participants from V503 arm of the base study who do not complete the 3-dose series receive 1 or 2 doses of V503, on Day 1, or Day 1 and Month 4 of the open label extension study.
Biological: V503
Participants from the placebo arm of the base study receive 3 doses of V503 on Day 1, Month 2 and Month 6 of the open label extension study.
Biological: V503
9-valent vaccine, HPV 6/11/16/18/31/33/45/52/58, L1 virus-like particle (VLP) 30/40/60/40/20/20/20/20/20 mcg per dose.
Also known as: 9vHPV vaccine, SILGARD®9, GARDASIL™9
0.9% sodium chloride (NaCL)
Base Study: Combined Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Anogenital Persistent Infection
Combined incidence of HPV type(s) 6/11/16/18-related anogenital persistent infection was defined to have occurred in a participant; 1) who is polymerase chain reaction (PCR) positive to at least one applicable HPV type(s) in 2 consecutive anogenital or biopsy samples from at least 2 consecutive visits 6 months (±1 month visit) or longer apart, or 2) who has a pathology diagnosis of condyloma, penile/perineal/perianal intraepithelial neoplasia, or penile, perineal or perianal cancer and PCR detection of at least one applicable HPV type(s) in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit with regardless of visit interval, prior to or following the biopsy showing HPV disease. Incidence was defined as the number of cases per 100 person-years of follow-up in both V503 and placebo arms. Per protocol, cases per 100 person-years is reported for applicable HPV type eligible participants with data available in the per-protocol efficacy population (PPE).
Time frame: Up to approximately 36 Months
Base Study: Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The participant recorded the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 5 days after any vaccination. The percentage of participants with an injection-site AE prompted on the VRC (redness/erythema, tenderness/pain, and swelling) is reported here for all randomized participants in the All Participants as Treated (APaT) population.
Time frame: Up to 5 days after any vaccination
Base Study: Percentage of Participants With ≥1 Systemic AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least 1 systemic AE is reported here for all randomized participants in the All Participants as Treated (APaT) population.
Time frame: Up to 15 days after any vaccination
Base Study: Percentage of Participants With ≥1 Serious Adverse Events (SAEs)
An SAE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, results in persistent/significant disability/incapacity, is a congenital birth defect, or is another important medical event. The percentage of participants who experienced at least 1 SAE is reported here for all randomized participants in the All Participants as Treated (APaT) population.
Time frame: Up to approximately 37 months
Base Study: Number of Participants With Elevated Oral Body Temperature
Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded using the vaccination report card (VRC). Per protocol, fever was defined as an oral temperature of ≥99.5°F(37.5°C). The number of participants who had at least 1 oral body temperature reading that was, \<99.5°F (\<37.5ºC), ≥99.5°F (≥37.5ºC) and \<100.4°F (38.0°C), or ≥100.4°F (38.0°C) and \<101.3°F(38.5°C), or ≥101.3°F(38.5°C) is reported here for all randomized participants in the APaT population with temperature data available.
Time frame: Up to 5 days after any vaccination
Base Study: Combined Incidence of HPV 31/33/45/52/58-related Anogenital Persistent Infection
Combined incidence of HPV type(s) 31/33/45/52/58-related anogenital persistent infection was defined to have occurred in a participant; 1) who is polymerase chain reaction (PCR) positive to at least 1 applicable HPV type(s) in 2 consecutive anogenital or biopsy samples from at least 2 consecutive visits 6 months (±1 month visit) or longer apart, or 2) who has a pathology diagnosis of condyloma, penile/perineal/perianal intraepithelial neoplasia, or penile, perineal or perianal cancer and PCR detection of at least 1 applicable HPV type in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit with regardless of visit interval, prior to or following the biopsy showing HPV disease. Incidence was defined as the number of cases per 100 person-years of follow-up in both V503 and placebo arms. Per protocol, cases per 100 person-years is reported for applicable HPV type(s) eligible participants with data available in the per-protocol efficacy population (PPE).
Time frame: Up to approximately 36 Months
Base Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - All Randomized Participants
Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for all randomized participants of the per-protocol immunogenicity population (PPI).
Time frame: Month 7
Base Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - Heterosexual Males (HM) Participant Subgroup
Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for the heterosexual males (HM) subgroup of the per-protocol immunogenicity population (PPI).
Time frame: Month 7
Base Study: Geometric Mean Titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58 - Males Who Have Sex With Males (MSM) Participant Subgroup
Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for the males who have sex with males (MSM) subgroup of the per-protocol immunogenicity population (PPI).
Time frame: Month 7
Base Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - All Randomized Participants
Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for all randomized participants of the per-protocol immunogenicity population (PPI).
Time frame: Month 7
Base Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - Heterosexual Males (HM) Participant Subgroup
Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for the heterosexual males (HM) subgroup of the per-protocol immunogenicity population (PPI).
Time frame: Month 7
Base Study: Percentage of Participants With Seroconversion to HPV 6/11/16/18/31/33/45/52/58 - Males Who Have Sex With Males (MSM) Participant Subgroup
Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for the males who have sex with males (MSM) subgroup of the per-protocol immunogenicity population (PPI).
Time frame: Month 7
| Milestone | V503 | Placebo | V503 → Open Label V503 Extension Study | Placebo → Open Label V503 Extension Study |
|---|---|---|---|---|
| Started | 529 | 530 | 0 | 0 |
| Vaccination 1: day 1 | 529 | 530 | 0 | 0 |
| Vaccination 2: month 2 | 523 | 518 | 0 | 0 |
| Vaccination 3: month 6 | 514 | 508 | 0 | 0 |
| Completed | 464 | 472 | 0 | 0 |
| Not completed | 65 | 58 | 0 | 0 |
| Withdrew: Withdrawal by subject | 57 | 42 | 0 | 0 |
| Withdrew: Lost to follow-up | 8 | 16 | 0 | 0 |
| Milestone | V503 | Placebo | V503 → Open Label V503 Extension Study | Placebo → Open Label V503 Extension Study |
|---|---|---|---|---|
| Started | 0 | 0 | 2 | 381 |
| Completed | 0 | 0 | 2 | 367 |
| Not completed | 0 | 0 | 0 | 14 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 10 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
Combined incidence of HPV type(s) 6/11/16/18-related anogenital persistent infection was defined to have occurred in a participant; 1) who is polymerase chain reaction (PCR) positive to at least one applicable HPV type(s) in 2 consecutive anogenital or biopsy samples from at least 2 consecutive visits 6 months (±1 month visit) or longer apart, or 2) who has a pathology diagnosis of condyloma, penile/perineal/perianal intraepithelial neoplasia, or penile, perineal or perianal cancer and PCR detection of at least one applicable HPV type(s) in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit with regardless of visit interval, prior to or following the biopsy showing HPV disease. Incidence was defined as the number of cases per 100 person-years of follow-up in both V503 and placebo arms. Per protocol, cases per 100 person-years is reported for applicable HPV type eligible participants with data available in the per-protocol efficacy population (PPE).
| Cases per 100 Person-years | V503 | Placebo |
|---|---|---|
| Base Study: Combined Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Anogenital Persistent Infection | 0.2 | 2.2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The participant recorded the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 5 days after any vaccination. The percentage of participants with an injection-site AE prompted on the VRC (redness/erythema, tenderness/pain, and swelling) is reported here for all randomized participants in the All Participants as Treated (APaT) population.
| Percentage of Participants | V503 | Placebo |
|---|---|---|
| Base Study: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) | 69.8 | 29.6 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least 1 systemic AE is reported here for all randomized participants in the All Participants as Treated (APaT) population.
| Percentage of Participants | V503 | Placebo |
|---|---|---|
| Base Study: Percentage of Participants With ≥1 Systemic AE | 20.2 | 19.8 |
An SAE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention, that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, results in persistent/significant disability/incapacity, is a congenital birth defect, or is another important medical event. The percentage of participants who experienced at least 1 SAE is reported here for all randomized participants in the All Participants as Treated (APaT) population.
| Percentage of Participants | V503 | Placebo |
|---|---|---|
| Base Study: Percentage of Participants With ≥1 Serious Adverse Events (SAEs) | 1.3 | 0.9 |
Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded using the vaccination report card (VRC). Per protocol, fever was defined as an oral temperature of ≥99.5°F(37.5°C). The number of participants who had at least 1 oral body temperature reading that was, \<99.5°F (\<37.5ºC), ≥99.5°F (≥37.5ºC) and \<100.4°F (38.0°C), or ≥100.4°F (38.0°C) and \<101.3°F(38.5°C), or ≥101.3°F(38.5°C) is reported here for all randomized participants in the APaT population with temperature data available.
| Participants | V503 | Placebo |
|---|---|---|
| <99.5°F (37.5°C) | 502 | 496 |
| ≥99.5°F (≥37.5ºC) and <100.4°F (38.0°C) | 19 | 22 |
| ≥100.4°F (38.0°C) and <101.3°F(38.5°C) | 1 | 1 |
| ≥101.3°F(38.5°C) | 5 | 7 |
Combined incidence of HPV type(s) 31/33/45/52/58-related anogenital persistent infection was defined to have occurred in a participant; 1) who is polymerase chain reaction (PCR) positive to at least 1 applicable HPV type(s) in 2 consecutive anogenital or biopsy samples from at least 2 consecutive visits 6 months (±1 month visit) or longer apart, or 2) who has a pathology diagnosis of condyloma, penile/perineal/perianal intraepithelial neoplasia, or penile, perineal or perianal cancer and PCR detection of at least 1 applicable HPV type in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit with regardless of visit interval, prior to or following the biopsy showing HPV disease. Incidence was defined as the number of cases per 100 person-years of follow-up in both V503 and placebo arms. Per protocol, cases per 100 person-years is reported for applicable HPV type(s) eligible participants with data available in the per-protocol efficacy population (PPE).
| cases per 100 Person-years | V503 | Placebo |
|---|---|---|
| Base Study: Combined Incidence of HPV 31/33/45/52/58-related Anogenital Persistent Infection | 0.7 | 1.9 |
Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for all randomized participants of the per-protocol immunogenicity population (PPI).
| mMU/mL | V503 | Placebo |
|---|---|---|
| Anti-HPV 6 | 927.3 (850.2 to 1011.3) | 21.1 (NA to 22.5) |
| Anti-HPV 11 | 716.5 (654.4 to 784.5) | NA (NA to NA) |
| Anti-HPV 16 | 3491.6 (3196.5 to 3814.0) | NA (NA to NA) |
| Anti-HPV 18 | 998.0 (904.3 to 1101.4) | 45.5 (43.4 to 47.7) |
| HPV-31 | 832.1 (753.3 to 919.2) | 15.4 (14.3 to 16.5) |
| HPV-33 | 489.8 (448.6 to 534.7) | 12.7 (11.9 to 13.4) |
| Anti-HPV 45 | 326.6 (293.7 to 363.2) | 8.5 (NA to 9.0) |
| Anti-HPV 52 | 390.5 (356.3 to 428.0) | 10.1 (9.5 to 10.8) |
| Anti-HPV 58 | 588.3 (537.7 to 643.6) | NA (NA to NA) |
Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for the heterosexual males (HM) subgroup of the per-protocol immunogenicity population (PPI).
| mMU/mL | V503 | Placebo |
|---|---|---|
| Anti-HPV 6 | 950.2 (866.8 to 1041.6) | 21.0 (NA to 22.6) |
| Anti-HPV 11 | 730.6 (664.4 to 803.4) | NA (NA to NA) |
| Anti-HPV 16 | 3608.3 (3288.6 to 3959.0) | NA (NA to NA) |
| Anti-HPV 18 | 1044.7 (942.7 to 1157.7) | 45.1 (42.9 to 47.3) |
| Anti-HPV 31 | 867.8 (780.7 to 964.7) | 15.1 (14.0 to 16.3) |
| Anti-HPV 33 | 495.4 (451.9 to 543.1) | 12.6 (11.8 to 13.4) |
| Anti-HPV 45 | 333.8 (298.4 to 373.5) | 8.4 (NA to 9.0) |
| Ant-HPV 52 | 408.7 (372.1 to 448.9) | 10.0 (9.3 to 10.7) |
| Anti-HPV 58 | 609.1 (554.2 to 669.4) | NA (NA to NA) |
Antibodies to the HPV types 6/11/16/18/31/33/45/52/58 contained in V503 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) is reported for both V503 and Placebo for the males who have sex with males (MSM) subgroup of the per-protocol immunogenicity population (PPI).
| mMU/mL | V503 | Placebo |
|---|---|---|
| Anti-HPV 6 | 740.2 (569.2 to 962.6) | 21.5 (NA to 27.5) |
| Anti-HPV 11 | 598.8 (438.7 to 817.3) | NA (NA to NA) |
| Anti-HPV 16 | 2599.5 (1957.4 to 3452.4) | NA (NA to NA) |
| Anti-HPV 18 | 677.4 (487.6 to 941.0) | 49.7 (42.1 to 58.6) |
| Anti-HPV 31 | 593.2 (446.0 to 789.0) | 17.7 (14.1 to 22.2) |
| Anti-HPV 33 | 443.6 (327.9 to 600.1) | 13.5 (11.5 to 16.0) |
| Anti-HPV 45 | 266.6 (190.1 to 373.8) | 9.1 (NA to 11.1) |
| Anti-HPV 52 | 262.9 (186.7 to 370.2) | 11.3 (9.0 to 14.2) |
| Anti-HPV 58 | 437.7 (327.8 to 584.5) | NA (NA to 8.4) |
Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for all randomized participants of the per-protocol immunogenicity population (PPI).
| Percentage of Participants | V503 | Placebo |
|---|---|---|
| Anti-HPV 6 cLIA ≥65 mMU/mL | 99.7 (98.6 to 100.0) | 3.5 (1.9 to 6.0) |
| Anti-HPV 11 cLIA ≥37 mMU/mL | 99.7 (98.6 to 100.0) | 4.1 (2.3 to 6.7) |
| Anti-HPV 16 cLIA ≥79 mMU/mL | 99.6 (98.4 to 99.9) | 4.3 (2.6 to 6.6) |
| Anti-HPV 18 cLIA ≥85 mMU/mL | 99.3 (97.9 to 99.9) | 8.3 (5.8 to 11.4) |
| Anti-HPV 31 cLIA ≥46 mMU/mL | 98.9 (97.3 to 99.6) | 5.6 (3.6 to 8.2) |
| Anti-HPV 33 cLIA ≥26 mMU/mL | 99.8 (98.8 to 100.0) | 11.1 (8.3 to 14.4) |
| Anti-HPV 45 cLIA ≥21 mMU/mL | 98.9 (97.4 to 99.6) | 9.0 (6.5 to 12.1) |
| Anti-HPV 52 cLIA ≥30 mMU/mL | 98.9 (97.4 to 99.6) | 4.2 (2.5 to 6.5) |
| Anti-HPV 58 cLIA ≥31 mMU/mL | 99.3 (98.1 to 99.9) | 1.5 (0.6 to 3.1) |
Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for the heterosexual males (HM) subgroup of the per-protocol immunogenicity population (PPI).
| Percentage of Participants | V503 | Placebo |
|---|---|---|
| Anti-HPV 6 cLIA ≥65 mMU/mL | 99.7 (98.5 to 100.0) | 3.5 (1.8 to 6.1) |
| Anti-HPV 11 cLIA ≥37 mMU/mL | 99.7 (98.5 to 100.0) | 4.4 (2.5 to 7.2) |
| Anti-HPV 16 cLIA ≥79 mMU/mL | 99.5 (98.2 to 99.9) | 3.7 (2.1 to 6.0) |
| Anti-HPV 18 cLIA ≥85 mMU/mL | 99.5 (98.1 to 99.9) | 7.6 (5.1 to 10.8) |
| Anti-HPV 31 cLIA ≥46 mMU/mL | 99.0 (97.4 to 99.7) | 5.2 (3.2 to 7.9) |
| Anti-HPV 33 cLIA ≥26 mMU/mL | 99.8 (98.6 to 100.0) | 11.4 (8.4 to 14.9) |
| Anti-HPV 45 cLIA ≥21 mMU/mL | 98.7 (97.1 to 99.6) | 8.5 (5.9 to 11.7) |
| Anti-HPV 52 cLIA ≥30 mMU/mL | 99.2 (97.8 to 99.8) | 3.8 (2.2 to 6.3) |
| Anti-HPV 58 cLIA ≥31 mMU/mL | 99.3 (97.9 to 99.8) | 1.7 (0.7 to 3.4) |
Percentage of seroconversion to each of HPV 6/11/16/18/31/33/45/52/58 at Month 7 based on competitive Luminex immunoassay (cLIA) from participant serum samples. Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive at 1 month post last dose Month 7. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL)) for HPV types were as follows: HPV Type 6: ≥65, HPV Type 11: ≥37; HPV Type 16: ≥79, HPV Type 18: ≥85, HPV Type 31: ≥46, HPV Type 33: ≥26, HPV Type 45: ≥21, HPV Type 52: ≥30, and HPV Type 58: ≥31. The percentage of participants with seroconversion is reported for both V503 and Placebo for the males who have sex with males (MSM) subgroup of the per-protocol immunogenicity population (PPI).
| Percentage of Participants | V503 | Placebo |
|---|---|---|
| Anti-HPV 6 cLIA ≥65 mMU/mL | 100.0 (91.0 to 100.0) | 3.6 (0.1 to 18.3) |
| Anti-HPV 11 cLIA ≥37 mMU/mL | 100.0 (91.0 to 100.0) | 0.0 (0.0 to 12.3) |
| Anti-HPV 16 cLIA ≥79 mMU/mL | 100.0 (92.1 to 100.0) | 9.5 (2.7 to 22.6) |
| Anti-HPV 18 cLIA ≥85 mMU/mL | 97.7 (88.0 to 99.9) | 14.3 (5.4 to 28.5) |
| Anti-HPV 31 cLIA ≥46 mMU/mL | 97.9 (88.9 to 99.9) | 8.9 (2.5 to 21.2) |
| Anti-HPV 33 cLIA ≥26 mMU/mL | 100.0 (92.5 to 100.0) | 8.7 (2.4 to 20.8) |
| Anti-HPV 45 cLIA ≥21 mMU/mL | 100.0 (91.8 to 100.0) | 13.3 (5.1 to 26.8) |
| Anti-HPV 52 cLIA ≥30 mMU/mL | 95.6 (84.9 to 99.5) | 7.0 (1.5 to 19.1) |
| Anti-HPV 58 cLIA ≥31 mMU/mL | 100.0 (92.6 to 100.0) | 0.0 (0.0 to 8.2) |
Collected over Up to approximately 55 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Base Study: V503 | 0/529 (0%) | 7/529 (1.3%) | 374/529 (70.7%) |
| Base Study: Placebo | 0/530 (0%) | 5/530 (0.9%) | 183/530 (34.5%) |
| Base Study: V503 → Open Label V503 Extension Study | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Base Study: Placebo → Open Label V503 Extension Study | 0/381 (0%) | 2/381 (0.5%) | 0/381 (0%) |
| Event | Base Study: V503 | Base Study: Placebo | Base Study: V503 → Open Label V503 Extension Study | Base Study: Placebo → Open Label V503 Extension Study |
|---|---|---|---|---|
| Gastroenteritis viralInfections and infestations | 0/529 | 0/530 | 0/2 | 1/381 |
| Ankle fractureInjury, poisoning and procedural complications | 0/529 | 0/530 | 0/2 | 1/381 |
| Colitis ulcerativeGastrointestinal disorders | 1/529 | 0/530 | 0/2 | 0/381 |
| AppendicitisInfections and infestations | 1/529 | 1/530 | 0/2 | 0/381 |
| COVID-19Infections and infestations | 1/529 | 1/530 | 0/2 | 0/381 |
| Campylobacter gastroenteritisInfections and infestations | 1/529 | 0/530 | 0/2 | 0/381 |
| Chronic tonsillitisInfections and infestations | 1/529 | 0/530 | 0/2 | 0/381 |
| Brain contusionInjury, poisoning and procedural complications | 1/529 | 0/530 | 0/2 | 0/381 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/529 | 0/530 | 0/2 | 0/381 |
| PeritonitisInfections and infestations | 0/529 | 1/530 | 0/2 | 0/381 |
| Event | Base Study: V503 | Base Study: Placebo | Base Study: V503 → Open Label V503 Extension Study | Base Study: Placebo → Open Label V503 Extension Study |
|---|---|---|---|---|
| Injection site painGeneral disorders | 360/529 | 122/530 | 0/2 | 0/381 |
| Injection site swellingGeneral disorders | 118/529 | 40/530 | 0/2 | 0/381 |
| Injection site erythemaGeneral disorders | 104/529 | 70/530 | 0/2 | 0/381 |
| PyrexiaGeneral disorders | 29/529 | 33/530 | 0/2 | 0/381 |
| Age, Continuous(Years) | V503 | Placebo | Total |
|---|---|---|---|
| Mean | 22.9 ± 2.1 | 22.8 ± 2.1 | 22.9 ± 2.1 |
| Sex: Female, Male(Participants) | V503 | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 529 | 530 | 1059 |
| Ethnicity (NIH/OMB)(Participants) | V503 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 529 | 530 | 1059 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | V503 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 529 | 530 | 1059 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Sexual Orientation Participant Subgroups(Participants) | V503 | Placebo | Total |
|---|---|---|---|
| Heterosexual Males (HM) | 473 | 474 | 947 |
| Males Who Have Sex With Males (MSM) | 56 | 56 | 112 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Nov 2020 to primary completion in Dec 2023, 37 months.
Results were first posted in Jan 2025, 1 year after primary completion.
Of 28 phase 3 interventional studies under Condylomata Acuminata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's 37 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent